Carlos Zambrano is the only Cub not allowed to have a meltdown

0 Comments

The Chicago Tribune’s Dan McNeil is no fan of Carlos Zambrano. After railing against his contract and going on about how he’s no Ted Lilly, McNeil predicts a Big-Z meltdown:

Put me down for the first week in May for not-so-Big Z’s first
implosion. Not sure if it will be getting tossed for undressing an
umpire or pulling up lame trying to stretch a double, but an eruption
is a certainty. Until the man-child proves he’s as right between the
ears as he is in the hips, I’m betting against the Cubs getting this
cat’s potential actualized.

I think the richest thing about this is how he uses Ted Lilly of all people to demonstrate just how awful Carlos Zambrano is, because Lilly is no stranger to drama himself.

No wait, that’s not the richest thing. The richest thing is that just last summer McNeil wrote that the Cubs’ biggest problem was that Lou Piniella was acting all calm and professional instead of being a combative jackass:

Unearthing bases. Kicking dirt. Spitting. Scratching.
Fighting one of his own players, as he did in Cincinnati with the
behemoth-sized Rob Dibble.

None of those outlandish behaviors will solve the Cubs’ most urgent
problems, but when a historically fiery manager ceases to breathe fire,
then you have a brand new problem to tack onto the list: resignation.

To sum up: you can get away with acting like a jerk if you’re Ted Lilly. You can not only get away with being a jerk but you damn well better be a jerk if you’re Lou Piniella. But Lord help you do those things and your name is Carlos Zambrano.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.